Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Powles, Thomas; E. Rosenberg, Jonathan; Sonpavde, Guru; Loriot, Yohann; Durán, Ignacio; Lee, Jae‐Lyun; Matsubara, Nobuaki; Vulsteke, Christof; Castellano, Daniel; Wu, Chunzhang; S. Campbell, Mary; Matsangou, Maria; P. Petrylak, Daniel

doi:10.1056/nejmoa2035807

Public

Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma

Published in New England Journal of Medicine • Feb 12, 2021

Authors:

Thomas Powles

Jonathan E. Rosenberg

Guru Sonpavde

Abstract

BACKGROUND: Patients with advanced urothelial carcinoma have poor overall survival after platinum-containing chemotherapy and programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor treatment. METHODS: We conducted a global, open-label, phase 3 trial of enfortumab vedot...

Subject

Medicine

Internal medicine

Hazard ratio

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!